This achievement opens new horizons and offers innovative treatment for patients suffering from sickle cell disease (SCD) and transfusion dependent beta-thalassemia (TDT), positioning Abu Dhabi as a ...

The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in ...

Known as Zynteglo in Europe where it is approved to treat the rare blood disorder beta-thalassemia, the gene therapy has been given the all-clear by bluebird’s scientists after reviewing the ...

Hedge funds are rapidly reducing their exposure to global information technology stocks, with the latest selloff marking the fastest decline in six months. Most of the selling is reported to be in ...

- Zimislecel (VX-880) pivotal trial on track to complete enrollment and dosing in H1 2025; Vertex expects to submit marketing applications to global regulators in 2026 - Vertex has completed ...

Low levels of hemoglobin may be a sign of an underlying health condition, such as anemia or cancer. Some dietary measures and supplements may help boost hemoglobin levels at home. Hemoglobin is an ...

In addition to the cell therapy programmes, for example, it is also working with CRISPR Therapeutics on CTX001, a gene-editing therapy for beta thalassemia and sickle cell disease. “We have ...

The Emirates Drug Establishment (EDE) in the UAE has granted market authorization for CASGEVY to treat patients aged 12 years and older who suffer from sickle cell disease with recurrent ...

The clinical characteristics of 152 children under the age of 15 with severe beta-thalassemia are summarized in Table 1. The median age was 4 years (IQR: 3–6 years), with 108 male and 44 female ...